vendredi 22 juin 2018

Onco Actu du 22 juin 2018

1. Biologie

Non-coding DNA reveals a route by which advanced prostate cancer resists treatment [Dana-Farber Cancer Institute]

Weighing in on weight loss in pancreatic cancer [Nature]

4. Dépistage, diagnostic et pronostic

Understanding medical tests: A new addition to our toolkit addressing sensitivity, specificity, and other core concepts [HealthNewsReview]

4.2 Dép., diag. & prono. - Génome

Lawmakers press genetic testing companies for details on their privacy policies [STAT]

4.3 Dép., diag. & prono. - Industriels

SOPHiA GENETICS acquires Interactive Biosoftware to drive growth and accelerate Data-Driven Medicine adoption around the world [SOPHiA GENETICS]

5.1 Traitements - Pré-clinique

Scripps Research study provides new clues to improving chemotherapies [The Scripps Research Institute]

5.10 Traitements - Essais

Nanobiotix Announces Positive Phase Ii/Iii Topline Data In Soft Tissue Sarcoma With Nbtxr3 [Nanobiotix]

5.12 Immunothérapies

We need more answers about immunotherapy for the elderly [STAT]

5.12.5 Immunothérapies - Pharma

U.S. Food and Drug Administration (FDA) Accepts Application for Opdivo Plus Low-Dose Yervoy for Treatment of First-Line Non-Small Cell Lung Cancer in Patients with Tumor Mutational Burden ≥10 mut/Mb [BMS]

5.2 Pharma

Mauled by a major setback, Incyte is pointing to a better future — but concedes it also had to scrap another failed study [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

Interested in joining the Committee for Advanced Therapies (CAT) to represent patients’ associations or clinicians? [EMA]

5.6.16 ESMO - Appareil digestif

Pembrolizumab Fails to Show Survival Benefit in PD-L1 ≥1 Gastric/GEJ Cancers [OncLive]

6.1 Observation

Higher body fat linked to lower breast cancer risk in younger women [UNC]

6.10.1 Politiques (USA)

As I predicted, the exploitation of desperate patients using right-to-try begins [Respectful Insolence]

Welcome to Right to Try [In the Pipeline]

6.12 Ethique

The Strategic Lies of Oncologists [NY Times]

6.6 Publications

Latest ranking of top research institutions show China coming on strong — with significant implications for biotech [EndPoints]

Some science journals that claim to peer review papers do not do so [The Economist]

6.9 Controverses

He was once a prominent cancer researcher. Then his gambling — and a finding of scientific misconduct — got in the way. [Retraction Watch]